Rescheduling to Schedule III — Strategic Breakthrough
Medical cannabis rescheduled to Schedule III; Glass House registered retail, cultivation and processing licenses with the DEA (Form 225 submitted) and completed an export application, positioning the company to pursue interstate commerce and international exports — potential to meaningfully expand addressable market and pricing dynamics outside California.
Maintained Full-Year Revenue and Production Guidance
Reiterated 2026 net revenue guidance of $235–245 million and production guidance of ~1.0 million pounds of biomass, signaling confidence in long-term scale despite near-term headwinds.
Q1 Production Above Guidance
Produced 152,000 pounds of wholesale biomass in Q1, ahead of guidance of 138,000 pounds (+10.1%), and in line with prior-year production (153,000).
Retail Outperformance in a Weak California Market
Retail sales of $11.9 million in Q1, up from $11.8 million a year ago, with same-store performance outperforming the California market (state declined ~8.5% for the period).
Greenhouse Capacity Expansion and Hemp Opportunity
Accelerated build-out of final 2/3 of Greenhouse 2 (total capacity >300,000 lbs biomass annually) and initial hemp production from Greenhouse 4 (current capability ~100,000 lbs annually, expandable to ~300,000 lbs); initial hemp harvest completed with anticipated sales this summer (international hemp/CBD markets).
Retail Joint Venture with Vireo Growth
Announced California retail joint venture with Vireo (50/50), combining dispensary portfolios and a supply agreement intended to improve pricing and profitability for both retail and wholesale operations; JV provides a potential 5-year off‑ramp to sell Glass House ownership to Vireo.
Improved Quarter-End Liquidity vs Year-End
Period ending cash and restricted cash of $27.9 million at quarter end, up from $23.4 million at year-end 2025 (+19%), and completed capital raise (~$22M drawn from a closed $25M ATM) to support greenhouse build-outs.